Ricevi le ultime notizie sulle azioni Longeveron con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di LGVN

Ultime notizie per

LONGEVERON INC-A

Longeveron

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Longeveron Inc

Press Releases

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Earnings

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

News

Financing

Longeveron Announces Up To $17.5 Million Public Offering

IPOs

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Health Care

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Management

Longeveron® Announces Key Leadership Updates

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

LGVN

Abpro Hldgs

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BioCardia

Bio Green Med Solution, Inc. - Common Stock

Bio Green Med Solution

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Curis

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Edesa Biotech

Geovax Labs

iBio

Imunon

Immuron Limited - American Depositary Shares

Immuron

Lisata Therapeutics

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

Palisade Bio

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Rallybio

SAB Biotherapeutics

Synlogic

Tharimmune

Roth Capital

HC Wainwright & Co.

Roth MKM

Maxim Group

EF Hutton

Screenshot 2024-11-15 at 7.50.34 PM

Biotech

General

BCLI

BRTX

MESO

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative&#39;s Inroads Bringing Its Stem Cell Therapies To Market

Comments

Longeveron Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO